Clinical Trials
9 trialsNCT02783625 2026-04-24
Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02512497 2025-09-19
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01638533 2025-02-07
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT01902225 2020-06-09
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
University of California, San Francisco
Phase 1 Completed
NCT01324310 2019-11-25
Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
Celgene
Phase 1 Completed
NCT01324323 2019-11-25
Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
Celgene
Phase 1 Completed
NCT00963274 2018-04-23
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Virginia Commonwealth University
Phase 1 Completed
NCT00019318 2015-04-29
Depsipeptide in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00024180 2013-01-31
FR901228 in Treating Patients With Hematologic Cancer
National Cancer Institute (NCI)
Phase 1 Completed